Literature DB >> 30148801

Mortality and survival in systemic sclerosis: a review of recent literature.

Dilli R Poudel1, Chris T Derk2.   

Abstract

PURPOSE OF REVIEW: Systemic sclerosis is a debilitating rheumatic disease with high morbidity and mortality. This review attempts to provide the most recent update on mortality and survival and their determinants in systemic sclerosis (SSc). RECENT
FINDINGS: SSc remains an uncommon rheumatic disease with high mortality. There have been attempts to devise more comprehensive but simpler scoring systems to prognosticate survival in SSc, which will influence triaging of patients and guide the utilization of aggressive treatment strategies.
SUMMARY: Updated literature review on mortality and survival in SSc has confirmed its high-case fatality but a slowly improving survival profile over time. It identifies some gaps in knowledge, especially in regards to ethnic differences.

Entities:  

Mesh:

Year:  2018        PMID: 30148801     DOI: 10.1097/BOR.0000000000000551

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  11 in total

1.  Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.

Authors:  Xinyu Ma; Rui Tang; Mei Luo; Zhuotong Zeng; Yaqian Shi; Bingsi Tang; Rong Xiao
Journal:  Clin Rheumatol       Date:  2021-06-02       Impact factor: 2.980

Review 2.  Pathophysiology and imaging of heart failure in women with autoimmune rheumatic diseases.

Authors:  Sophie I Mavrogeni; George Markousis-Mavrogenis; Loukia Koutsogeorgopoulou; Theodoros Dimitroulas; Vasiliki Vartela; Angelos Rigopoulos; Michel Noutsias; Genovefa Kolovou
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

3.  Dihydroartemisinin alleviates skin fibrosis and endothelial dysfunction in bleomycin-induced skin fibrosis models.

Authors:  Rui Li; Hanlin Yin; Juan Wang; Dongyi He; Qingran Yan; Liangjing Lu
Journal:  Clin Rheumatol       Date:  2021-05-19       Impact factor: 2.980

4.  Determining progression of scleroderma-related interstitial lung disease.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Myung Sim; Grace Hyun Kim; Jonathan Goldin; Philip J Clements
Journal:  J Scleroderma Relat Disord       Date:  2018-12-17

5.  Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.

Authors:  David Roofeh; Oliver Distler; Yannick Allanore; Christopher P Denton; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2020-03-05

6.  In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.

Authors:  Yukihiro Kitanaga; Emiko Imamura; Yutaka Nakahara; Hidehiko Fukahori; Yasutomo Fujii; Satoshi Kubo; Shingo Nakayamada; Yoshiya Tanaka
Journal:  Rheumatology (Oxford)       Date:  2020-08-01       Impact factor: 7.580

7.  Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention.

Authors:  Aryeh Fischer; Nina M Patel; Elizabeth R Volkmann
Journal:  Open Access Rheumatol       Date:  2019-12-09

8.  Gut disease in systemic sclerosis - new approaches to common problems.

Authors:  Jessica Zhu; Tracy Frech
Journal:  Curr Treatm Opt Rheumatol       Date:  2019-02-07

9.  A Method for Isolating and Culturing Skin Cells: Application to Endothelial Cells, Fibroblasts, Keratinocytes, and Melanocytes From Punch Biopsies in Systemic Sclerosis Skin.

Authors:  Pauline Henrot; Paôline Laurent; Emeline Levionnois; Damien Leleu; Catherine Pain; Marie-Elise Truchetet; Muriel Cario
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

10.  Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews.

Authors:  Anna-Maria Hoffmann-Vold; Elisabeth Bendstrup; Theodoros Dimitroulas; Roger Hesselstrand; Antonio Morais; Ritva Peltomaa; Vanessa Smith; Joep Welling; Madelon C Vonk; Wim A Wuyts
Journal:  Rheumatology (Oxford)       Date:  2021-12-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.